Doris is 85 and suffers from moisture build up in her eye, what some call wet eye. She is on Medicare and gets treated with Eylea, a Regeneron product, every 4-5 weeks. Each treatment costing $6,200. That is more than $70,000 per year even though Doris never made more than $40,000 while working. … Continue reading Regeneron’s Eylea: Pulling Open the Curtain on Drug Costs
Senator McConnell's Dilemma: To Serve Patients or Investors? When evaluating health care investments it is important to analyze the structure of leading drug and medical equipment companies. A close look indeed reveals a derivative driven system in which private equity and hedge funds increase demand for drug payments by purchasing the rights … Continue reading Is Patient Health Being Mortgaged via Derivatives as Homes Were During the Financial Crisis?